Literature DB >> 21237582

Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers.

Bridget F Koontz1, Matvey Tsivian, Vladimir Mouraviev, Leon Sun, Zeljko Vujaskovic, Judd Moul, W Robert Lee.   

Abstract

PURPOSE: To evaluate the primary Gleason grade (GG) in Gleason score (GS) 7 prostate cancers for risk of non-organ-confined disease with the goal of optimizing radiotherapy treatment option counseling.
METHODS: One thousand three hundred thirty-three patients with pathologic GS7 were identified in the Duke Prostate Center research database. Clinical factors including age, race, clinical stage, prostate-specific antigen at diagnosis, and pathologic stage were obtained. Data were stratified by prostate-specific antigen and clinical stage at diagnosis into adapted D'Amico risk groups. Univariate and multivariate analyses were performed evaluating for association of primary GG with pathologic outcome.
RESULTS: Nine hundred seventy-nine patients had primary GG3 and 354 had GG4. On univariate analyses, GG4 was associated with an increased risk of non-organ-confined disease. On multivariate analysis, GG4 was independently associated with seminal vesicle invasion (SVI) but not extracapsular extension. Patients with otherwise low-risk disease and primary GG3 had a very low risk of SVI (4%).
CONCLUSIONS: Primary GG4 in GS7 cancers is associated with increased risk of SVI compared with primary GG3. Otherwise low-risk patients with GS 3+4 have a very low risk of SVI and may be candidates for prostate-only radiotherapy modalities.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21237582     DOI: 10.1016/j.ijrobp.2010.11.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study.

Authors:  R Mathieu; M Moschini; B Beyer; K M Gust; T Seisen; A Briganti; P Karakiewicz; C Seitz; L Salomon; A de la Taille; M Rouprêt; M Graefen; S F Shariat
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-10       Impact factor: 5.554

2.  Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.

Authors:  Phillip M Pierorazio; Patrick C Walsh; Alan W Partin; Jonathan I Epstein
Journal:  BJU Int       Date:  2013-03-06       Impact factor: 5.588

3.  Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.

Authors:  Matthew J Boyer; Michael A Papagikos; Rex Kiteley; Zeljko Vujaskovic; Jackie Wu; W Robert Lee
Journal:  Radiat Oncol       Date:  2017-01-13       Impact factor: 3.481

4.  The performance of the new prognostic grade and stage groups in conservatively treated prostate cancer.

Authors:  Cheng Chen; Ye Chen; Lin-Kun Hu; Chang-Chuan Jiang; Ren-Fang Xu; Xiao-Zhou He
Journal:  Asian J Androl       Date:  2018 Jul-Aug       Impact factor: 3.285

5.  Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions.

Authors:  Eiman Siddig Ahmed; Lubna S Elnour; Rowa Hassan; Emmanuel E Siddig; Mintu Elsa Chacko; Eman T Ali; Mona A Mohamed; Abdalla Munir; Mohamed S Muneer; Nouh S Mohamed; Ali M M Edris
Journal:  BMC Res Notes       Date:  2020-06-17

6.  Impact of positive surgical margin on biochemical recurrence in localized prostate cancer.

Authors:  Wonchul Lee; Bumjin Lim; Yoon Soo Kyung; Choung-Soo Kim
Journal:  Prostate Int       Date:  2021-03-09

7.  Cyclin D1 expression in prostate carcinoma.

Authors:  R A Pereira; R C Ravinal; R S Costa; M S Lima; S Tucci; V F Muglia; R B dos Reis; G E B Silva
Journal:  Braz J Med Biol Res       Date:  2014-05-02       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.